HARVARD MEDICAL SCHOOL

SPAULDING REHABILITATION NETWORK

MASSACHUSETTS GENERAL HOSPITAL

Network Meta-analysis:
Principles and applications



Felipe Fregni, MD, PhD, MMSc, MPH, MEd
Kevin Pacheco-Barrios, MD, MSc
Neuromodulation Center
Harvard Medical School

Disclaimer

- No conflicts of interest

Objectives

- By the end of this session, we hope you will understand the:

  - What?
  - Why?
  - How? (in Stata)

  Of Network Meta-analysis

Two big problems with modern medicine

- Contradictory studies on almost every topic
- Flood of new data

The (quick) story of meta-analysis



??
Best treatment for breast cancer



I-square 50-62%

Apple and oranges problem

Using the force of heterogeneity to understand more!



Treatment for breast cancer appears to differ by cancer stage. Overall benefit for women with late cancer but absent evidence of benefit for early stages

Huge advantages of meta-analysis

- Understand how different treatments work in different settings
- Find when treatments are harmful
- Compost huge volumes of data into something useable
- Understand the quality of the evidence
- Policy-making bodies love them
- Highly cited and influential



JAMA Ioannidis 2006

(Old) New problem

Traditional meta-analysis

Is treatment A better than treatment B?

(Old) New problem



Traditional meta-analysis

Is treatment A better than treatment B?

The real clinical question



Which of the six available treatments is the most effective and safest?

Is treatment B better than treatment F?

Networks: using indirect comparisons

- If we know how much taller building B is to A and how much taller is C to A, we know how much taller is B compared to C

- For any pair B and C, typical difference of C over B = difference of C over A minus difference of B over A

Indirect comparison

- We can obtain an indirect estimate of treatment effect for B vs C from trials comparing A v B and A v C



Treatment effect BC = Treatment effect AC – Treatment effect AB

Variance BC = variance AC + variance AB

Example: Toothpaste versus gel



Example: Toothpaste versus gel



Even when there are no studies – we can estimate that toothpaste is better than gel

Using direct and indirect effects



Mixed effects: more precise?



Indirect SMD = -0.15 (0.0037)

Direct SMD = 0.04 (0.01)

Mixed SMD = -0.10 (0.0027)

Problem of combining information



Criticism of indirect comparisons

- Indirect comparison respects randomization but it is not randomized evidence
- Indirect and mixed effects (toothpaste versus gel) can answer policy questions taking a broad approach (e.g., which is the safest of all treatments)

- BUT

- They use non-randomized evidence and extra considerations are needed

Is network meta-analysis valid?

- That one can learn about B versus C via A
- (That one can learn about toothpaste versus gel via placebo)



Is the common treatment similar?





Treatment A is similar when it appears in AB and AC trials

Plausible when A is placebo given in different forms
(e.g. injection versus pill)?

Is the common treatment similar?





For example, placebo rinse and placebo toothpaste might not be comparable as the mechanical action of brushing might have a different effect on caries

Issue must be addressed when building the network (at the start of the project)

Are the populations in the network similar?



Just like in conventional meta-analysis, there are ways to explore and understand heterogeneity and inconsistency

PRACTICAL APPLICATIONS OF NMA

1. Show the geometry of the evidence (antipsychotics in schizophrenia)



Leucht Lancet 2013

2. Show effects of drugs in which there are no trials



Palmer in press 2014

3. Rank treatments in order of best to worst (which antidepressant would you not want!)



Ranking for efficacy (solid line) and acceptability (dotted line). Ranking: probability to be the best treatment, to be the second best, the third best and so on, among the 12 comparisons).

4. Display in single graphic entire relative evidence for a condition or drug



Cipriani Lancet 2011

Application in STATA

OPEN ACCESS Freely available online

PLOS ONE

Graphical Tools for Network Meta-Analysis in STATA

Anna Chaimani[1], Julian P. T. Higgins[2,3], Dimitris Mavridis[1,4], Panagiota Spyridonos[5], Georgia Salanti[1]*

1 Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece, 2 School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 3 Centre for Reviews and Dissemination, University of York, York, United Kingdom, 4 Department of Primary Education, University of Ioannina, Ioannina, Greece, 5 Department of Medical Physics, School of Medicine, University of Ioannina, Ioannina, Greece

Abstract

Network meta-analysis synthesizes direct and indirect evidence in a network of trials that compare multiple interventions and has the potential to rank the competing treatments according to the studied outcome. Despite its usefulness network meta-analysis is often criticized for its complexity and for being accessible only to researchers with strong statistical and computational skills. The evaluation of the underlying model assumptions, the statistical technicalities and presentation of the results in a concise and understandable way are all challenging aspects in the network meta-analysis methodology. In this paper we aim to make the methodology accessible to non-statisticians by presenting and explaining a series of graphical tools via worked examples. To this end, we provide a set of STATA routines that can be easily employed to present the evidence base, evaluate the assumptions, fit the network meta-analysis model and interpret its results.

Citation: Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G (2013) Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE 8(10): e76654. doi:10.1371/journal.pone.0076654

Editor: Benjamin Haibe-Kains, Institut de recherches cliniques de Montréal (IRCM), Canada

Received May 16, 2013; **Accepted** August 27, 2013; **Published** October 3, 2013

Funding: AC, DM and GS received funding from the European Research Council (IMMA 260559 project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: gsalanti@cc.uoi.gr

Exercise versus drugs in absence of trials (or why you should exercise more!)



Naci BMJ 2014